Neuromuscular
News
National Online Directory of Amyotrophic Lateral Sclerosis Specialists Launched
Monday, February 04, 2019—A national online database of healthcare providers (HCPs) who treat amyotrophic lateral sclerosis (ALS) has been launched by Mitsubishi Tanabe Pharma America (MTPA). The …
Neuromuscular Community Survey Identifies Key Issues
Thursday, January 17, 2019—The Muscular Dystrophy Association (MDA) has announced results of a landmark survey that asked more than 3,000 people affected by neuromuscular disease (NMD) about their key a…
Phase 3 Trial of Dioscorea japonica Extracts To Be Initiated for Treatment of Pain From Diabetic Neuropathy
Tuesday, January 08, 2019—The planned initiation of a phase 3 double-blind, placebo controlled, 12-week study of Dioscorea japonica extracts (NB-01; Neurobo, Boston, MA) for pain relief in pa…
American Academy of Neurology Call for Uniformity in Brain Death Standards
Thursday, January 03, 2019—Noting that only 1 state, Nevada, has adopted legislation requiring use of medically accepted guidelines for determining brain death, the American Academy of Neurology (AAN) i…
Reliability of Ultrasound Measurements in Patients with Amyotrophic Lateral Sclerosis
Friday, December 28, 2018—In a study published in the journal Muscle & Nerve, researchers suggest diagnostic ultrasound may provide a reliable biomarker for amyotrophic lateral scle
FDA Accepts Application for Genetic Treatment of Spinal Muscular Atrophy Type 1
Wednesday, December 05, 2018—The Food and Drug Administration (FDA) has accepted the Biologics License Application for onasemnogene abeparvovec-xxxx (AVXS-101, Zolgensma; AveXis, Bannockburn, Illinoi…
Dystonia and Spasticity Patients May Become Immune to Toxin Treatment
Tuesday, December 04, 2018—People with dystonia or spasticity can get relief from botulinum toxin type A, but a new study published online in Neurology shows that 15% of people treated with th…
FDA Approves Amifampridine for Lambert-Eaton Myasthenic Syndrome
Monday, December 03, 2018—The FDA has approved amifampridine (Firdapse, Catalyst Pharmaceuticals, Coral Gables, FL) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. This…
